Portal de Periódicos da CAPES

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

2009; Wiley; Volume: 115; Issue: 22 Linguagem: Inglês

10.1002/cncr.24575

1097-0142

Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, Stefan Faderl, Carlos E. Bueso‐Ramos, Lynne V. Abruzzo, Sherry Pierce, Jianqin Shan, Jean‐Pierre J. Issa, Guillermo Garcia‐Manero,

Advanced biosensing and bioanalysis techniques

To define the prognosis in myelodysplastic syndrome (MDS) and deletion 5q with or without other cytogenetic abnormalities.Patients with MDS ( or =2 abnormalities or chromosome 7 abnormality. Only 93 patients (3.4% of total) had lower risk MDS (international prognostic scoring system low or intermediate 1) and deletion 5q; their median survival was 29 months (2-year survival 60%), and ranged from 13-41 months depending on the presence or absence of additional chromosomal abnormalities. Among 198 patients with MDS with deletion 5q and <10% blasts (a subset now often offered lenalidomide), the median survival was 12 months. Monosomy 5 was significantly more frequently associated with advanced MDS and with other chromosomal abnormalities.This study provided baseline expectations of outcome in different MDS subsets and deletion 5q.